Inozyme Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights
12 nov. 2020 06h00 HE
|
Inozyme Pharma Inc.
– Submitted CTA for INZ-701 for the treatment of ENPP1 deficiency to United Kingdom regulatory agency – – Received Rare Pediatric Disease and Fast Track Designations for INZ-701 for the treatment...
Inozyme Pharma Appoints Kevin B. Johnson, Ph.D., MBA, as Senior Vice President, Regulatory Affairs
09 nov. 2020 06h00 HE
|
Inozyme Pharma Inc.
BOSTON, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal...
Inozyme Pharma Appoints Yves Sabbagh, Ph.D., as Senior Vice President and Chief Scientific Officer
13 oct. 2020 06h00 HE
|
Inozyme Pharma Inc.
– Dr. Sabbagh Brings More Than 20 Years of Experience in Rare Genetic Disorders and Mineral Metabolism Research Development Programs – – Company Announces Retirement of David Thompson, Ph.D. – –...
Inozyme Pharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights
03 sept. 2020 16h05 HE
|
Inozyme Pharma Inc.
Upsized IPO in July 2020 raised $128.8 million in gross proceeds Submitted IND for INZ-701 for the treatment of ENPP1 deficiency; currently on FDA clinical hold pending completion of ongoing GLP...
Inozyme Pharma Announces Closing of Initial Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
30 juil. 2020 16h01 HE
|
Inozyme Pharma Inc.
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (“Inozyme”) (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of...
Inozyme Pharma Announces Pricing of Initial Public Offering
23 juil. 2020 21h30 HE
|
Inozyme Pharma Inc.
BOSTON, July 23, 2020 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (“Inozyme”) (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of...
Inozyme Pharma Acquires ENPP1 Deficiency Program Assets from Alexion Pharmaceuticals
17 juil. 2020 18h05 HE
|
Inozyme Pharma Inc.
Acquisition expands Inozyme’s intellectual property portfolio for the development of novel therapies for ENPP1 deficiency Alexion acquires ownership stake in Inozyme BOSTON, July 17, 2020 (GLOBE...